BACKGROUND: Intensity-modulated radiotherapy (IMRT) using the simultaneous integrated boost (SIB) method was designed for treating @entity11 . The purpose of this study was to investigate feasibility of this treatment. METHODS: Between December 2000 and November 2002, six @entity1 with @entity11 were enrolled in this study. IMRT delivered 70 Gy/28 fractions (fr)/daily 2.5 Gy to the gross @entity5 volume (GTV) and 56 Gy/28 fr/daily 2.0 Gy to the surrounding @entity4 defined as the clinical target volume annulus (CTV-a). The feasibility of the treatment was assessed from both physical and clinical points of view. RESULTS: No delay due to @entity6937 was observed in any of the @entity1 . The @entity5 recurred locoregionally in five of the six @entity1 . The @entity463 ( @entity463 ) recurred in two @entity1 during the radiotherapy and in three @entity1 at 5.4, 4.0 and 7.0 months after the start of radiotherapy. The sites of recurrence or progression were local in the GTV in four @entity1 and in one @entity1 subependymal dissemination was observed. Three @entity1 , two with GBMs and one with @entity816 , died of the disease at 4, 16 and 7 months after the start of radiotherapy, respectively. CONCLUSIONS: The treatment of 70 Gy/28 fr/daily 2.5 Gy to the GTV and 56 Gy/28 fr/daily 2.0 Gy to the CTV-a was feasible both physically and clinically.

Feasibility study of the simultaneous integrated boost (SIB) method for XXXX using intensity-modulated radiotherapy (IMRT).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity11 :: ('MESH:D005910', 'Disease') :: ['malignant gliomas'] @entity816 :: ('MESH:D001254', 'Disease') :: ['anaplastic astrocytoma'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'glioblastoma'] @entity6937 :: ('MESH:D054508', 'Disease') :: ['acute radiation toxicity']
@entity11 :: (MESH:D005910,Disease) :: ['malignant gliomas']
